Urogen Pharma Ltd (URGN) Expected to Announce Earnings of -$1.22 Per Share

Brokerages forecast that Urogen Pharma Ltd (NASDAQ:URGN) will report earnings per share (EPS) of ($1.22) for the current quarter, Zacks reports. Zero analysts have issued estimates for Urogen Pharma’s earnings, with the lowest EPS estimate coming in at ($1.33) and the highest estimate coming in at ($1.11). Urogen Pharma posted earnings per share of ($1.14) in the same quarter last year, which indicates a negative year over year growth rate of 7%. The company is expected to issue its next quarterly earnings results on Tuesday, August 13th.

According to Zacks, analysts expect that Urogen Pharma will report full year earnings of ($5.41) per share for the current financial year, with EPS estimates ranging from ($5.83) to ($5.06). For the next fiscal year, analysts forecast that the company will post earnings of ($3.89) per share, with EPS estimates ranging from ($6.27) to ($1.66). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Urogen Pharma.

Urogen Pharma (NASDAQ:URGN) last announced its earnings results on Thursday, May 9th. The company reported ($1.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.01. Urogen Pharma had a negative net margin of 4,296.08% and a negative return on equity of 61.24%.

A number of equities analysts have recently issued reports on the stock. Zacks Investment Research lowered shares of Urogen Pharma from a “buy” rating to a “hold” rating in a research report on Thursday, May 16th. Cowen restated a “buy” rating on shares of Urogen Pharma in a research report on Monday, May 6th. Stifel Nicolaus restated a “buy” rating and set a $63.00 target price on shares of Urogen Pharma in a research report on Tuesday, March 5th. HC Wainwright restated a “buy” rating and set a $75.00 target price on shares of Urogen Pharma in a research report on Friday, March 1st. Finally, Oppenheimer restated a “buy” rating on shares of Urogen Pharma in a research report on Tuesday, March 19th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $64.17.

In related news, insider Mark Schoenberg sold 1,991 shares of Urogen Pharma stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $37.30, for a total value of $74,264.30. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 10.50% of the company’s stock.

A number of large investors have recently bought and sold shares of the stock. FMR LLC grew its position in Urogen Pharma by 5.8% in the 1st quarter. FMR LLC now owns 588,203 shares of the company’s stock valued at $21,728,000 after buying an additional 32,200 shares during the last quarter. Wildcat Capital Management LLC grew its position in Urogen Pharma by 27.2% in the 1st quarter. Wildcat Capital Management LLC now owns 779,003 shares of the company’s stock valued at $28,776,000 after buying an additional 166,509 shares during the last quarter. Morgan Stanley grew its position in Urogen Pharma by 65.4% in the 1st quarter. Morgan Stanley now owns 24,923 shares of the company’s stock valued at $920,000 after buying an additional 9,856 shares during the last quarter. Man Group plc grew its position in Urogen Pharma by 49.5% in the 1st quarter. Man Group plc now owns 178,996 shares of the company’s stock valued at $6,612,000 after buying an additional 59,260 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its position in Urogen Pharma by 267.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 59,445 shares of the company’s stock valued at $2,196,000 after buying an additional 43,266 shares during the last quarter. Hedge funds and other institutional investors own 81.77% of the company’s stock.

Shares of URGN opened at $37.74 on Friday. The company has a market cap of $518.93 million, a PE ratio of -7.86 and a beta of 1.33. Urogen Pharma has a 12-month low of $34.61 and a 12-month high of $62.78.

About Urogen Pharma

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The company's lead product candidates, UGN-101 and UGN-102 are proprietary formulations of the chemotherapy drug mitomycin, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.

Recommended Story: Trading Strategy Methods for Individual Investors

Get a free copy of the Zacks research report on Urogen Pharma (URGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Urogen Pharma (NASDAQ:URGN)

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.